Veru’s (VERU) Buy Rating Reaffirmed at Brookline Capital Management

Brookline Capital Management reaffirmed their buy rating on shares of Veru (NASDAQ:VERU) in a research report report published on Friday morning, Zacks.com reports.

Several other equities analysts have also issued reports on the stock. HC Wainwright reissued a buy rating and issued a $6.00 price target on shares of Veru in a report on Monday, June 22nd. Zacks Investment Research raised shares of Veru from a hold rating to a buy rating and set a $4.00 price target for the company in a report on Saturday, May 16th. ValuEngine lowered shares of Veru from a buy rating to a hold rating in a report on Monday, June 1st. Finally, Oppenheimer reissued a buy rating and issued a $9.00 price target on shares of Veru in a report on Friday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $6.33.

VERU opened at $2.75 on Friday. The company has a fifty day moving average price of $3.09 and a two-hundred day moving average price of $3.44. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.68 and a current ratio of 1.04. Veru has a 52 week low of $1.67 and a 52 week high of $4.74. The firm has a market capitalization of $206.75 million, a PE ratio of -18.33 and a beta of 0.33.

Veru (NASDAQ:VERU) last released its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.02). Veru had a negative return on equity of 31.14% and a negative net margin of 25.53%. Equities analysts forecast that Veru will post -0.14 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of VERU. Advisor Group Holdings Inc. lifted its position in Veru by 199.1% in the 2nd quarter. Advisor Group Holdings Inc. now owns 10,515 shares of the company’s stock valued at $35,000 after acquiring an additional 7,000 shares in the last quarter. Argent Wealth Management LLC lifted its position in Veru by 37.0% in the 1st quarter. Argent Wealth Management LLC now owns 18,521 shares of the company’s stock valued at $58,000 after acquiring an additional 5,000 shares in the last quarter. HighTower Advisors LLC bought a new stake in Veru in the 2nd quarter valued at $62,000. Leap Investments LP lifted its position in Veru by 38.5% in the 2nd quarter. Leap Investments LP now owns 25,200 shares of the company’s stock valued at $84,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in Veru in the 4th quarter valued at $90,000. 16.33% of the stock is currently owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

See Also: Conference Calls